Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 9/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 8/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.37 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.36 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL290322 | 0.82 | TSHR (0.48) | TSHRMAOBMAOANOS3NOS1 | |
| SCHEMBL29825887 | 0.82 | TSHR (0.48) | TSHRMAOBMAOANOS3NOS1 | |
| SCHEMBL29175249 | 0.79 | BIRC5 (0.39) | TSHRMAOBMAOANOS3NOS1 | |
| SCHEMBL30475151 | 0.78 | MAOB (0.61) | MAOBMAOANOS3NOS1NOS2 | |
| SCHEMBL1395661 | 0.78 | MAOB (0.61) | MAOBMAOANOS3NOS1NOS2 | |
| SCHEMBL8404526 | 0.78 | CYP2A6 (0.42) | TSHRMAOBMAOANOS3NOS1 | |
| SCHEMBL5158400 | 0.77 | SIGMAR1 (0.36) | PYCR1 | |
| SCHEMBL2022697 | 0.77 | PYCR1 (0.43) | PYCR1 | |
| SCHEMBL119203 | 0.77 | TSHR (0.50) | TSHRS1PR1EGLN2 | |
| SCHEMBL277588 | 0.76 | TSHR (0.52) | TSHREGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 936 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114805107-B | n-alpha arylation method of nitrogen-containing heterocycle realized by photocatalysis | 哈尔滨工业大学（深圳） | 2024-03-26 | — | — | CN | claimed |
| CN-115160134-B | Preparation method of 4-bromo-2-methyl benzoate | 无锡科华生物科技有限公司 | 2023-10-10 | — | — | CN | claimed |
| CN-115160134-A | Preparation method of 4-bromo-2-methyl benzoate | 无锡科华生物科技有限公司 | 2022-10-11 | — | — | CN | claimed |
| EP-4720065-A1 | PRMT5 INHIBITORS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-04-08 | — | — | EP | disclosed |
| CN-121627548-A | Synthesis method of 4-bromo-2-fluoro-6-methylbenzonitrile | 上海毕得医药科技股份有限公司 | 2026-03-10 | — | — | CN | disclosed |
| EP-4051680-B1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-12391697-B2 | Condensed bi-heterocycles as inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250236610-A1 | 3-[(1H-PYRAZOL-4-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | BEIGENE, LTD. (KY) | 2025-07-24 | — | — | US | disclosed |
| EP-3782994-B1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY INC (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20250122173-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LTD (GB) | 2025-04-17 | — | — | US | disclosed |
| CN-119823097-A | PHD inhibitor compounds, compositions and uses | 阿克比治疗有限公司 | 2025-04-15 | — | — | CN | disclosed |
| WO-1998050358-A1 | INDOLE DERIVATIVES HAVING COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ANTAGONIST ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998042670-A1 | NOVEL PYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRA PHARMACEUTICALS LTD. (GB) | 1998-10-01 | — | — | WO | disclosed |
| EP-0858451-A1 | PHARMACEUTICALLY ACTIVE QUINAZOLINE COMPOUNDS | Astra Pharmaceuticals Limited (GB) | 1998-08-19 | — | — | EP | disclosed |
| WO-1997038977-A1 | AMINOISOQUINOLINES AND AMINOTHIENOPYRIDINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | ASTRA PHARMACEUTICALS LTD. (GB) | 1997-10-23 | — | — | WO | disclosed |
| WO-1997030970-A1 | METHOD FOR PRODUCING UNSYMMETRICALLY SUBSTITUTED BIPHENYLS | GREAT LAKES CHEMICAL KONSTANZ GMBH (DE) | 1997-08-28 | — | — | WO | disclosed |
| EP-0498722-B1 | Bicyclic nitrogen compounds, their preparation, intermediates obtained, their use as pharmaceuticals and pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1997-07-30 | — | — | EP | disclosed |
| WO-1997014686-A1 | PHARMACEUTICALLY ACTIVE QUINAZOLINE COMPOUNDS | ASTRA PHARMACEUTICALS LIMITED (GB) | 1997-04-24 | — | — | WO | disclosed |
| EP-0498722-A1 | Bicyclic nitrogen compounds, their preparation, intermediates obtained, their use as pharmaceuticals and pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1992-08-12 | — | — | EP | disclosed |
| US-4269834-A | Copper complexes of isoquinazolines | NAUTA WIJBE T | 1981-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122173-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK1, ROCK2, RHOA | TSHR 3834/4885MAOB 2161/4885MAOA 2052/4885 |
| US-12391697-B2 | Condensed bi-heterocycles as inhibiting agents for Bruton's tyrosine kinase | ABL1, CDK1, CDK2 | TSHR 3078/4885MAOB 379/4885MAOA 1048/4885 |
| US-20250236610-A1 | 3-[(1H-PYRAZOL-4-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | HIPK1, HIPK3, HIPK2 | TSHR 4360/4885MAOB 3595/4885MAOA 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.